GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (NAS:IBRX) » Definitions » Pretax Margin %

ImmunityBio (ImmunityBio) Pretax Margin % : -335,325.00% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is ImmunityBio Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. ImmunityBio's Pre-Tax Income for the three months ended in Mar. 2024 was $-134.13 Mil. ImmunityBio's Revenue for the three months ended in Mar. 2024 was $0.04 Mil. Therefore, ImmunityBio's pretax margin for the quarter that ended in Mar. 2024 was -335,325.00%.

The historical rank and industry rank for ImmunityBio's Pretax Margin % or its related term are showing as below:

IBRX' s Pretax Margin % Range Over the Past 10 Years
Min: -199151.99   Med: -37456   Max: -7278.07
Current: -199151.99


IBRX's Pretax Margin % is ranked worse than
98.25% of 1030 companies
in the Biotechnology industry
Industry Median: -155.98 vs IBRX: -199151.99

ImmunityBio Pretax Margin % Historical Data

The historical data trend for ImmunityBio's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunityBio Pretax Margin % Chart

ImmunityBio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
-7,278.07 -37,360.83 -37,456.00 -173,869.17 -93,873.31

ImmunityBio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -32,384.17 -337,104.88 -116,636.59 -167,952.52 -335,325.00

Competitive Comparison of ImmunityBio's Pretax Margin %

For the Biotechnology subindustry, ImmunityBio's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ImmunityBio's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmunityBio's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where ImmunityBio's Pretax Margin % falls into.



ImmunityBio Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

ImmunityBio's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-583.892/0.622
=-93,873.31 %

ImmunityBio's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-134.13/0.04
=-335,325.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ImmunityBio  (NAS:IBRX) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


ImmunityBio Pretax Margin % Related Terms

Thank you for viewing the detailed overview of ImmunityBio's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmunityBio (ImmunityBio) Business Description

Traded in Other Exchanges
Address
3530 John Hopkins Court, San Diego, CA, USA, 92121
ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. Geographically, the company operates in United States and Europe. Majority of the revenue is generated from Europe.
Executives
Patrick Soon-shiong director, 10 percent owner, officer: See remarks 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
California Capital Equity, Llc 10 percent owner 10182 CULVER BOULEVARD, CULVER CITY CA 90232
Nant Capital, Llc 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Cambridge Equities, Lp 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Mp 13 Ventures, Llc 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Michael D Blaszyk director C/O NANTKWEST, INC., 2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
John Owen Brennan director C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Wesley Clark director C/O ARGYLE SECURITY ACQUISITION CORP., 200 CONCORD PLAZA, SUITE 700, SAN ANTONIO TX 78216
Regan J Lauer officer: Chief Accounting Officer 4250 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA 92037
Richard Adcock officer: Chief Executive Officer C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Cheryl Cohen director C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Linda Maxwell director 1040 SPRING STREET, SILVER SPRING NC 27709
Christobel Selecky director C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
David C. Sachs officer: Chief Financial Officer C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Frederick W Driscoll director

ImmunityBio (ImmunityBio) Headlines

From GuruFocus